Dr. Wahl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Fl Univ
Ann Arbor, MI 48109Phone+1 734-936-4300
Education & Training
University of MichiganResidency, Radiation Oncology, 2012 - 2017
St Joseph Mercy Ann ArborInternship, Transitional Year, 2012 - 2013
University of Michigan Medical SchoolClass of 2012
Certifications & Licensure
MI State Medical License 2017 - 2027
American Board of Radiology Radiation Oncology
Publications & Presentations
PubMed
- Reirradiation Special Medical Physics Consultations: Lessons Learned from Nearly 3000 Courses of Treatment.Kelly C Paradis, Charles Mayo, Charles K Matrosic, Joann I Prisciandaro, Benjamin S Rosen
International Journal of Radiation Oncology, Biology, Physics. 2025-03-09 - A phase II study of multiparametric MR-guided high-dose response-adaptive radiotherapy with concurrent temozolomide in patients with newly diagnosed glioblastoma: Resu...Michelle M Kim, Madhava P Aryal, Krithika Suresh, Benjamin S Rosen, Hemant Parmar
International Journal of Radiation Oncology, Biology, Physics. 2025-03-07 - Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer.Victoria M Valvo, Qiang Zhang, Long Jiang, Erin A Holcomb, Ashley N Pearson
Molecular Cancer Therapeutics. 2024-12-17
Journal Articles
- No Sugar Added: A New Strategy to Inhibit Glioblastoma Receptor Tyrosine KinasesDaniel R Wahl, Theodore S Lawrence, Clinical Cancer Research
Press Mentions
Small Lab Leans on Integrity to Become Nationally-Recognized Phenotyping CenterJune 8th, 2021- Rackham Student Raises over $80,000 for University of Michigan NeurosurgeonMarch 15th, 2021
Can Patient-Derived Xenografts Predict Treatment Responses in Glioblastoma?July 18th, 2019- Join now to see all
Grant Support
- Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.WASHINGTON UNIVERSITY2022–2027
- Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.WASHINGTON UNIVERSITY2022–2027
- Targeting Nucleotide Metabolism to Overcome Therapy Resistance in GlioblastomaUNIVERSITY OF MICHIGAN AT ANN ARBOR2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
